Stay updated with breaking news from Nasdaq vrca. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Free Report) insider Christopher G. Hayes sold 33,789 shares of the stock in a transaction on Monday, July 24th. The stock was sold at an average price of $4.83, for a total transaction of $163,200.87. Following the transaction, the insider now directly owns 81,925 shares in the company, valued […] ....
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Free Report) insider Christopher G. Hayes sold 33,789 shares of the business’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $4.83, for a total transaction of $163,200.87. Following the completion of the transaction, the insider now directly owns […] ....
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Free Report) Director Paul B. Manning bought 200,000 shares of Verrica Pharmaceuticals stock in a transaction on Monday, July 24th. The stock was acquired at an average cost of $5.02 per share, for a total transaction of $1,004,000.00. Following the acquisition, the director now owns 7,851,128 shares in the […] ....
Verrica Pharmaceuticals (NASDAQ:VRCA – Get Rating) and Ainos (OTCMKTS:AIMD – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation. Institutional & Insider Ownership 24.9% of Verrica Pharmaceuticals shares are […] ....
BML Capital Management LLC acquired a new position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Rating) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,110,605 shares of the company’s stock, valued at approximately $3,054,000. Verrica Pharmaceuticals accounts for approximately 2.9% of BML Capital Management […] ....